Antimicrobial treatment of Capnocytophaga infections

Int J Antimicrob Agents. 2007 Apr;29(4):367-73. doi: 10.1016/j.ijantimicag.2006.10.005. Epub 2007 Jan 23.

Abstract

Capnocytophaga spp. are normal inhabitants of the oropharyngeal flora. They are also involved in periodontal diseases or animal bites, complicated by septicaemia with dissemination to a great variety of sites, both in immunocompetent and immunocompromised hosts. This review will focus on their pathogenesis, spectrum of clinical infections and susceptibility to disinfectants and antibiotics. The spread of beta-lactamase-producing strains limits the use of beta-lactams as first-line treatments, underlying the necessity to test the in vitro susceptibility of clinical strains. Many antimicrobial treatments have been used, despite an absence of randomised studies and guidelines regarding the duration of treatment according to infected sites. Imipenem/cilastatin, clindamycin or beta-lactamase inhibitor combinations are always effective and their use can be recommended in all infections.

Publication types

  • Review

MeSH terms

  • Animals
  • Anti-Bacterial Agents / therapeutic use*
  • Bacteremia / drug therapy
  • Bacteremia / etiology
  • Bacteremia / microbiology
  • Capnocytophaga / drug effects
  • Capnocytophaga / pathogenicity*
  • Cilastatin / therapeutic use
  • Clindamycin / therapeutic use
  • Endocarditis, Bacterial / drug therapy
  • Endocarditis, Bacterial / etiology
  • Gram-Negative Bacterial Infections / complications
  • Gram-Negative Bacterial Infections / drug therapy*
  • Gram-Negative Bacterial Infections / microbiology
  • Humans
  • Imipenem / therapeutic use
  • Immunocompromised Host
  • Microbial Sensitivity Tests
  • beta-Lactam Resistance
  • beta-Lactamases / drug effects
  • beta-Lactamases / metabolism
  • beta-Lactams / pharmacology
  • beta-Lactams / therapeutic use

Substances

  • Anti-Bacterial Agents
  • beta-Lactams
  • Cilastatin
  • Clindamycin
  • Imipenem
  • beta-Lactamases